Published in J Neurochem on February 09, 2011
Phenolic compounds prevent amyloid β-protein oligomerization and synaptic dysfunction by site-specific binding. J Biol Chem (2012) 1.05
Validation and Characterization of a Novel Peptide That Binds Monomeric and Aggregated β-Amyloid and Inhibits the Formation of Neurotoxic Oligomers. J Biol Chem (2015) 0.84
The 12/15-lipoxygenase as an emerging therapeutic target for Alzheimer's disease. Trends Pharmacol Sci (2015) 0.79
Insight into the stability of cross-β amyloid fibril from VEALYL short peptide with molecular dynamics simulation. PLoS One (2012) 0.79
The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotype. Front Cell Neurosci (2015) 0.78
RNA aptamer probes as optical imaging agents for the detection of amyloid plaques. PLoS One (2014) 0.78
Effects of lateral ventricular transplantation of bone marrow-derived mesenchymal stem cells modified with brain-derived neurotrophic factor gene on cognition in a rat model of Alzheimer's disease. Neural Regen Res (2012) 0.78
Anti-aggregating effect of the naturally occurring dipeptide carnosine on aβ1-42 fibril formation. PLoS One (2013) 0.78
Seeding plaques in Alzheimer's disease. J Neurochem (2012) 0.76
Bryostatin-1 vs. TPPB: dose-dependent APP processing and PKC-α, -δ, and -ε isoform activation in SH-SY5Y neuronal cells. J Mol Neurosci (2012) 0.76
Derailed intraneuronal signalling drives pathogenesis in sporadic and familial Alzheimer's disease. Biomed Res Int (2014) 0.76
The 5-Lipoxygenase as modulator of Alzheimer's γ-secretase and therapeutic target. Brain Res Bull (2016) 0.75
Synthesis of tetrahydroxybiphenyls and tetrahydroxyterphenyls and their evaluation as amyloid-β aggregation inhibitors. Bioorg Med Chem Lett (2013) 0.75
Pharmacokinetics, Safety and Tolerability of Melissa officinalis Extract which Contained Rosmarinic Acid in Healthy Individuals: A Randomized Controlled Trial. PLoS One (2015) 0.75
The Contribution of α-Synuclein Spreading to Parkinson's Disease Synaptopathy. Neural Plast (2017) 0.75
Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med (2011) 3.95
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Prospective 10-year surveillance of human prion diseases in Japan. Brain (2010) 2.41
Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res (2004) 2.23
Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem (2003) 1.64
Polyneuropathy caused by cobalt-chromium metallosis after total hip replacement. Muscle Nerve (2010) 1.62
A neuropathological study of autosomal-dominant chorea-acanthocytosis with a mutation of VPS13A. Acta Neuropathol (2008) 1.59
Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer's disease. Eur J Nucl Med Mol Imaging (2007) 1.58
Prevalence of spinocerebellar degenerations in the Hokuriku district in Japan. Neuroepidemiology (2009) 1.49
Immunoglobulin light-chain (AL) amyloidosis with myasthenic symptoms and echocardiographic features of dilated cardiomyopathy. Intern Med (2006) 1.46
R-spondin, a novel gene with thrombospondin type 1 domain, was expressed in the dorsal neural tube and affected in Wnts mutants. Biochim Biophys Acta (2004) 1.46
Effect of sample size for normal database on diagnostic performance of brain FDG PET for the detection of Alzheimer's disease using automated image analysis. Nucl Med Commun (2008) 1.42
Rapid scanning protocol for brain (18)F-FDG PET: a validation study. J Nucl Med (2005) 1.41
Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. Neurobiol Aging (2004) 1.36
Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway. Am J Pathol (2009) 1.30
Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem (2006) 1.27
SORL1 is genetically associated with late-onset Alzheimer's disease in Japanese, Koreans and Caucasians. PLoS One (2013) 1.23
REVIEW: Curcumin and Alzheimer's disease. CNS Neurosci Ther (2010) 1.22
Acute encephalitis caused by intrafamilial transmission of enterovirus 71 in adult. Emerg Infect Dis (2008) 1.19
Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's beta-amyloid fibrils in vitro. Biochim Biophys Acta (2004) 1.10
CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res (2008) 1.10
Cross-seeding effects of amyloid β-protein and α-synuclein. J Neurochem (2012) 1.08
Kinetic modeling and determination of reaction constants of Alzheimer's beta-amyloid fibril extension and dissociation using surface plasmon resonance. Biochemistry (2002) 1.08
Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Neuropharmacology (2005) 1.05
Phenolic compounds prevent amyloid β-protein oligomerization and synaptic dysfunction by site-specific binding. J Biol Chem (2012) 1.05
Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: effects of correction on normal databases and a multicentre study. Eur J Nucl Med Mol Imaging (2011) 1.04
Association of an 11-12 kDa protease-resistant prion protein fragment with subtypes of dura graft-associated Creutzfeldt-Jakob disease and other prion diseases. J Gen Virol (2003) 1.03
Myoclonic involuntary movement associated with chronic manganese poisoning. J Neurol Sci (2002) 1.02
Ferulic acid destabilizes preformed beta-amyloid fibrils in vitro. Biochem Biophys Res Commun (2005) 1.01
The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of beta-amyloid fibrils (fAbeta), as well as destabilize preformed fAbeta. Curr Pharm Des (2006) 0.99
Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci (2005) 0.98
Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease. Ann Nucl Med (2004) 0.98
Brain FDG PET study of normal aging in Japanese: effect of atrophy correction. Eur J Nucl Med Mol Imaging (2005) 0.97
Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro. Biol Psychiatry (2002) 0.95
Allodynia in the flank after thalamic stroke. J Clin Neurosci (2006) 0.94
B-cell neurolymphomatosis confined to the peripheral nervous system. J Neurol Sci (2007) 0.94
Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer's disease. Biochim Biophys Acta (2006) 0.92
Critical role of interfaces and agitation on the nucleation of Abeta amyloid fibrils at low concentrations of Abeta monomers. Biochim Biophys Acta (2010) 0.92
The anti-amyloidogenic effect is exerted against Alzheimer's beta-amyloid fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure. Biochemistry (2007) 0.92
Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. Neuropharmacology (2007) 0.91
Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. Exp Neurol (2004) 0.91
Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis. J Neuroimmunol (2008) 0.90
Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's beta-amyloid fibrils in vitro. J Neurochem (2002) 0.90
Relationships between clinicopathological features and cerebrospinal fluid biomarkers in Japanese patients with genetic prion diseases. PLoS One (2013) 0.90
Medical procedures and risk for sporadic Creutzfeldt-Jakob disease, Japan, 1999-2008. Emerg Infect Dis (2009) 0.90
Comparison of 18F-FDG PET and optimized voxel-based morphometry for detection of Alzheimer's disease: aging effect on diagnostic performance. J Nucl Med (2007) 0.90
The risk of iatrogenic Creutzfeldt-Jakob disease through medical and surgical procedures. Neuropathology (2009) 0.90
Epidemiology of familial amyloid polyneuropathy in Japan: Identification of a novel endemic focus. J Neurol Sci (2008) 0.88
Effect of melatonin on α-synuclein self-assembly and cytotoxicity. Neurobiol Aging (2011) 0.88
Peripheral neuropathy associated with chronic natural killer cell lymphocytosis. J Neurol Sci (2005) 0.88
Familial Parkinson disease mutations influence α-synuclein assembly. Neurobiol Dis (2011) 0.87
A linear lesion along the brachial plexus on FDG-PET in neurolymphomatosis. Intern Med (2008) 0.86
A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic. Dement Geriatr Cogn Disord (2010) 0.86
Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro. J Neurosci Res (2007) 0.86
Vitamin A and Alzheimer's disease. Geriatr Gerontol Int (2011) 0.86
Vitamin A has anti-oligomerization effects on amyloid-β in vitro. J Alzheimers Dis (2011) 0.86
Duration of prion disease is longer in Japan than in other countries. J Epidemiol (2011) 0.86
Two different clinical phenotypes of Creutzfeldt-Jakob disease with a M232R substitution. J Neurol (2007) 0.86
Reduced expression of endogenous secretory receptor for advanced glycation endproducts in hippocampal neurons of Alzheimer's disease brains. Arch Histol Cytol (2007) 0.85
An autopsy case of an aged patient with spinocerebellar ataxia type 2. Neuropathology (2010) 0.85
Deciphering the pathogenesis of sporadic Creutzfeldt-Jakob disease with codon 129 M/V and type 2 abnormal prion protein. Acta Neuropathol Commun (2013) 0.85
MRI of segmental zoster paresis. Neurology (2005) 0.85
Insight into the frequent occurrence of dura mater graft-associated Creutzfeldt-Jakob disease in Japan. J Neurol Neurosurg Psychiatry (2013) 0.85
Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol (2011) 0.85
In vitro differentiation of lineage-negative bone marrow cells into microglia-like cells. Eur J Neurosci (2010) 0.84
Preformed beta-amyloid fibrils are destabilized by coenzyme Q10 in vitro. Biochem Biophys Res Commun (2005) 0.84
The efficacy of radiation monotherapy for Tolosa-Hunt syndrome. J Neurol (2009) 0.84
Anti-fibrillogenic and fibril-destabilizing activity of nicotine in vitro: implications for the prevention and therapeutics of Lewy body diseases. Exp Neurol (2007) 0.84
Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease. J Neurol (2011) 0.84
Microscopic polyangitis presenting with temporal arteritis and multiple cranial neuropathies. J Neurol Sci (2007) 0.83
Charcot-Marie-Tooth disease type 2D with a novel glycyl-tRNA synthetase gene (GARS) mutation. J Neurol (2010) 0.83
[Epidemiology and surveillance system of prion disease in Japan]. Nihon Rinsho (2007) 0.83
Alpha-synuclein assembly as a therapeutic target of Parkinson's disease and related disorders. Curr Pharm Des (2008) 0.83
Multicentre multiobserver study of diffusion-weighted and fluid-attenuated inversion recovery MRI for the diagnosis of sporadic Creutzfeldt-Jakob disease: a reliability and agreement study. BMJ Open (2012) 0.83
Graft-related disease progression in dura mater graft-associated Creutzfeldt-Jakob disease: a cross-sectional study. BMJ Open (2013) 0.83
A clinical phenotype of distal hereditary motor neuronopathy type II with a novel HSPB1 mutation. J Neurol Sci (2008) 0.83
Cervical flexion myelopathy in a patient showing apparent long tract signs: a severe form of Hirayama disease. Joint Bone Spine (2011) 0.83
Development of a culture system to induce microglia-like cells from haematopoietic cells. Neuropathol Appl Neurobiol (2014) 0.82
The influence of PRNP polymorphisms on human prion disease susceptibility: an update. Acta Neuropathol (2015) 0.82
Ophthalmic surgery in prion diseases. Emerg Infect Dis (2007) 0.82
Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in vitro. Exp Neurol (2009) 0.82
Comparative study of pre-operative thymic imaging and pathology in patients with myasthenia gravis. J Clin Neurosci (2004) 0.81
Early and persistent sensory-psychiatric symptoms in an inherited prion disease with a PrP P105L mutation. J Neurol (2002) 0.81
Non-steroidal anti-inflammatory drugs as anti-amyloidogenic compounds. Curr Pharm Des (2008) 0.81
Cerebrospinal Fluid from Alzheimer's disease patients promotes amyloid beta-protein oligomerization. J Alzheimers Dis (2010) 0.81
Effect of cognitive and aerobic training intervention on older adults with mild or no cognitive impairment: a derivative study of the nakajima project. Dement Geriatr Cogn Dis Extra (2012) 0.81
Glucose metabolism and gray-matter concentration in apolipoprotein E ε4 positive normal subjects. Neurobiol Aging (2011) 0.81
Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease. Dement Geriatr Cogn Disord (2007) 0.81
Cerebrospinal fluid from patients with multiple system atrophy promotes in vitro α-synuclein fibril formation. Neurosci Lett (2011) 0.81
Cerebrospinal fluid of Alzheimer patients promotes beta-amyloid fibril formation in vitro. Neurobiol Dis (2005) 0.81
Multiple skull metastases from hepatocellular carcinoma successfully treated with radiotherapy. Intern Med (2010) 0.81
Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's beta-amyloid fibrils in vitro. Neurochem Int (2005) 0.80
Creutzfeldt-Jakob disease associated with a V203I homozygous mutation in the prion protein gene. Prion (2014) 0.80
Characteristics of progressive multifocal leukoencephalopathy clarified through internet-assisted laboratory surveillance in Japan. BMC Neurol (2012) 0.80
The first Japanese patient with variant Creutzfeldt-Jakob disease (vCJD). Neuropathology (2009) 0.80
Polyethylene glycol interferon alpha-2b-induced immune-mediated polyradiculoneuropathy. Intern Med (2009) 0.80
Acute autonomic sensory and motor neuropathy associated with central nervous system disturbance. J Clin Neurosci (2006) 0.80
Unintended effects of cardiovascular drugs on the pathogenesis of Alzheimer's disease. PLoS One (2013) 0.80
Effects of sex hormones on Alzheimer's disease-associated β-amyloid oligomer formation in vitro. Exp Neurol (2011) 0.80